S-ClassAbout S-Class
C
CBLLAI Stock Diagnostic Report
Ceribell expects $114M-$117M 2026 revenue as CMS finalizes delirium NTAP up to $2,171 per patient
Ceribell has recorded strong revenue growth, bolstered by the final approval of CMS for the Delirium NTAP, and has raised its revenue outlook for 2026.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$19.299999237060547Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support15.96 — echo this pre-calculated value verbatim, do NOT change it
Near-Term Resistance20.24 — echo this pre-calculated value verbatim, do NOT change it
02
FUNDAMENTALS
Financial & Fundamental Analysis
The 2026 revenue guidance has been set at $114M to $117M, and Q2 revenue reached $28.1 million, reflecting a 33% growth compared to the same period last year, demonstrating accelerated financial growth.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $19.30 is positioned just below the 20-day high resistance level of $20.24, and the RSI of 61.5 along with a trading volume of 1.23 suggests a phase where attempts for further upward movement coexist with short-term profit-taking.
Support15.96 — echo this pre-calculated value verbatim, do NOT change it
Resistance20.24 — echo this pre-calculated value verbatim, do NOT change it
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
CMS has finalized a delirium NTAP (New Technology Add-on Payment) of up to $2,171 per patient, securing a direct catalyst for future performance growth.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-11)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.